Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer
Conclusions:
We have found that TbetaRIII is required for migration and invasion in vitro and xenograft growth in vivo. We also show that TbetaRIII-KD elevates expression of integrin-alpha2, which is required for the reduced migration and invasion, as determined by siRNA knockdown studies of both TbetaRIII and integrin-alpha2. Overall, our results indicate a potential mechanism in which TbetaRIII modulates integrin-alpha2 expression to effect MSL cell migration, invasion, and tumorigenicity. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 1, 2014 Category: Cancer & Oncology Authors: Bojana Jovanovi¿J BeelerMichael PickupAnna ChytilAgnieszka GorskaWilliam AshbyBrian LehmannAndries ZijlstraJennifer PietenpolHarold Moses Source Type: research
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition
Conclusions:
PIK3CA mutations are associated with classical markers of good prognosis and signatures of PI3K pathway activity. The presence of a PIK3CA mutation does not preclude a response to neoadjuvant anastrozole treatment. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 30, 2014 Category: Cancer & Oncology Authors: Elena López-KnowlesCorrinne SegalQiong GaoIsaac Garcia-MurillasNicholas TurnerIan SmithLesley-Ann MartinMitch Dowsett Source Type: research
Relationship of PIK3CA mutation and pathway activity with anti-proliferative response to aromatase inhibition
Conclusions:
PIK3CA mutations are associated with classical markers of good prognosis and signatures of PI3K pathway activity. The presence of a PIK3CA mutation does not preclude a response to neoadjuvant anastrozole treatment. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 30, 2014 Category: Cancer & Oncology Authors: Elena López-KnowlesCorrinne SegalQiong GaoIsaac Garcia-MurillasNicholas TurnerIan SmithLesley-Ann MartinMitch Dowsett Source Type: research
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells
Conclusions:
Lestaurtinib amplifies the ability of the PARP1 inhibitor AG14361 to kill BRCA1 mutant and wild type breast cancer cells, at least in part, by inhibiting NF-kappaB signaling. Each of these drugs has been approved for clinical trials for several different cancers, thus, their combination should be applicable for a breast cancer trial in the future. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 24, 2014 Category: Cancer & Oncology Authors: Guelaguetza Vazquez-OrtizCristine ChisholmXiaoling XuTyler LahusenCuiling LiSrilatha SakamuruRuili HuangCraig ThomasMenghang XiaChuxia Deng Source Type: research
Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity
Conclusions:
H4K20me3 was reduced in cancerous regions of breast-tumor tissue, as in other types of tumor. Reduced H4K20me3 level can be used as an independent marker of poor prognosis in breast cancer patients. Most importantly, this study suggests that a reduced level of H4K20me3 increases the invasiveness of breast cancer cells in a HER2-independent manner. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 22, 2014 Category: Cancer & Oncology Authors: Yuhki YokoyamaAyaka MatsumotoMiki HiedaYoshimi ShinchiEri OgiharaMai HamadaYu NishiokaHiroshi KimuraKatsuhide YoshidomeMasahiko TsujimotoNariaki Matsuura Source Type: research
A revised clinico-pathological surrogate definition of Luminal A intrinsic breast cancer subtype
Conclusions:
This updated pathological definition of intrinsic molecular subtypes may maximize the number of patients classified as having 'Luminal A-like' intrinsic subtype for whom use of cytotoxic drugs could be at large avoided. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 20, 2014 Category: Cancer & Oncology Authors: Patrick MaisonneuveDavide DisalvatoreNicole RotmenszGiuseppe CuriglianoMarco ColleoniSilvia DellapasquaGiancarlo PruneriMauro MastropasquaAlberto LuiniFabio BassiGianmatteo PaganiGiuseppe VialeAron Goldhirsch Source Type: research
The molecular landscape of the normal human breast ¿ defining normal
A key approach in understanding how breast cancer can occur is to determine the regulatory pathways at play in the normal breast and to identify precisely the normal developmental mechanisms subverted during early breast cancer progression. Using normal human breast tissue samples, Pardo and colleagues have identified the gene targets and pathways displaying fluctuating expression as a consequence of the menstrual cycle. Detailed characterization of how the human breast functions in its normal state, and how this may be perturbed at its earliest point, will provide a critical step toward the prevention of breast cancer. (S...
Source: Breast Cancer Research - June 20, 2014 Category: Cancer & Oncology Authors: Heidi HiltonJ Graham Source Type: research
Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population
Conclusions:
Genetic variants on top of conventional risk factors can improve the risk prediction of breast cancer in Chinese women. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 18, 2014 Category: Cancer & Oncology Authors: Charmaine LeeAstrid IrwantoAgus SalimJian-min YuanJianjun LiuWoon KohMikael Hartman Source Type: research
Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes
A number of available treatments provide relief of menopausal symptoms and prevention of postmenopausal osteoporosis. However, as breast safety is a major concern, new options are needed, particularly agents with an improved mammary safety profile. Results from several large randomized and observational studies have shown an association between hormone therapy, particularly combined estrogen-progestin therapy, and a small increased risk of breast cancer and breast pain or tenderness. In addition, progestin-containing hormone therapy has been shown to increase mammographic breast density, which is an important risk factor f...
Source: Breast Cancer Research - June 18, 2014 Category: Cancer & Oncology Authors: Carolyn SmithRichard SantenBarry KommSebastian Mirkin Source Type: research
Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer
Conclusion:
Protein mass profiling by MS has revealed five serum proteins which, in combination, can distinguish between serum from women with breast cancer and healthy control subjects with high sensitivity and specificity. The 5-protein panel significantly predicts recurrence-free survival in women with ER-negative tumors and may have value in the management of these patients. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 16, 2014 Category: Cancer & Oncology Authors: Liping ChungKatrina MooreLeo PhillipsFrances BoyleDeborah MarshRobert Baxter Source Type: research
Construction and evaluation of a novel humanized HER2-specific chimeric receptor
Conclusions:
This study shows that novel chA21 scFv based HER2 specific-CAR T cells not only recognized and killed HER2-positive breast and ovarian cancer cells ex vivo, but also induced regression of experimental breast cancer in vivo. Our data supports further exploration of the HER2 CAR T cell-therapy for HER2-expressing cancers. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 11, 2014 Category: Cancer & Oncology Authors: Meili SunHuan ShiChuanyong LiuJie LiuXianqiang LiuYuping Sun Source Type: research
Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells
Conclusions:
The described heterotypic co-culture system will prove useful for further characterization of the molecular mechanisms mediating interactions between human normal or neoplastic breast epithelial cells and the stroma, and will provide a framework to test the relevance of the ever-increasing number of oncogenomic alterations identified in human breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 10, 2014 Category: Cancer & Oncology Authors: Stephan DussHeike BrinkhausAdrian BritschgiErik CabuyDaniel FreyDirk SchaeferMohamed Bentires-Alj Source Type: research
A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer
A novel database of 1,172 mouse mammary tumor samples from 26 different major oncogenic mouse mammary tumor models reveals molecular features of mouse models and their relationships to human breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 5, 2014 Category: Cancer & Oncology Authors: Daniel HollernEran Andrechek Source Type: research
Adjusting the incidence increase when screening for statistical lead time will always give estimates of overdiagnosis close to zero
No description available (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 4, 2014 Category: Cancer & Oncology Authors: Per-Henrik Zahl Source Type: research
Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study
IntroductionThe MRE11A-RAD50-Nibrin (MRN) complex plays several critical roles related to repair of DNA double-strand breaks. Inherited mutations in the three components predispose to genetic instability disorders and the MRN genes have been implicated in breast cancer susceptibility, but the underlying data are not entirely convincing. Here, we address two related questions: (1) are some rare MRN variants intermediate-risk breast cancer susceptibility alleles, and if so (2) do the MRN genes follow a BRCA1/BRCA2 pattern wherein most susceptibility alleles are protein truncating variants, or do they follow an ATM/CHEK2 patt...
Source: Breast Cancer Research - June 3, 2014 Category: Cancer & Oncology Authors: Francesca DamiolaMaroulio PertesiJavier OliverFlorence Le Calvez-KelmCatherine VoegeleErin YoungNivonirina RobinotNathalie ForeyGeoffroy DurandMaxime ValléeKayoko TaoTerrell RoaneGareth WilliamsJohn HopperMelissa SoutheyIrene AndrulisEsther JohnDavid Gol Source Type: research
